

**Supplementary Table 1.** Demographic and clinical characteristics of the patients at baseline.

	<b>Exenatide (n=23)</b>	<b>Placebo (n=22)</b>	<b>p-value</b>
<b>Age (year) – mean ± SD [range]</b>	37.1 ± 10.6 [19-65]	34.5 ± 10.1 [19-56]	0.40
<b>Sex (male / female) – no. (%)</b>	11 (48) / 12 (52)	10 (45) / 12 (55)	0.87
<b>Ethnicity (caucasian / mongolian) – no. (%)</b>	21 (91) / 2 (9)	19 (86) / 3 (14)	0.60
<b>Illness duration (weeks) – mean ± SD [range]</b>	689 ± 463 [38-1404]#	578 ± 426 [26-1404]	0.41
<b>Education (years) – mean ± SD [range]</b>	12.6 ± 2.9 [8-18]	12.1 ± 2.6 [7-20]	0.51
<b>Current smoker – no. (%)</b>	7 (30)	1 (5)	0.02
<b>Body weight (kg) – mean ± SD [range]</b>	117.1 ± 16.7 [84.4-150.7]	110.6 ± 17.7 [88.2-149.7]	0.21
<b>BMI (kg/m<sup>2</sup>) – mean ± SD [range]</b>	39.2 ± 3.8 [31.0-48.0]	38.4 ± 6.1 [30.1-55.1]	0.59
<b>Diagnosis</b>			
<b>Schizophrenia, F20.X – no. (%)</b>	21 (91)	20 (91)	-
<b>Schizoaffective disorders, F25.X – no. (%)</b>	2 (9)	2 (9)	
<b>Antipsychotic medication</b>			
<b>Typical monotherapy – no. (%)</b>	1 (4)	1 (5)	0.97
<b>Atypical monotherapy – no. (%)</b>	15 (65)	11 (50)	0.30
<b>Polypharmacy – no. (%)</b>	7 (30)	10 (45)	0.30

# One observation missing.